Work

Abstract PS2-02-08: Real-world PARP inhibitor use and clinical outcomes in US patients with HER2-negative metastatic breast cancer

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps2-02-08

Authors: S. Yadav, Q. Li, Z. Tan, K. E. Mishkin, J. F. Hayes, X. Xu, F. J. Couch

Institutions: Mayo Clinic, AstraZeneca (United States), AstraZeneca (Canada), Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129409963

Cites:

Cited by:

Related to: